Sionna Therapeutics Files 8-K on Financials
Ticker: SION · Form: 8-K · Filed: Mar 20, 2025 · CIK: 2036042
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
Sionna Therapeutics dropped an 8-K on March 20th detailing their financials. Check it out.
AI Summary
Sionna Therapeutics, Inc. filed an 8-K on March 20, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located at 21 Hickory Drive, Suite 500, Waltham, MA 02451.
Why It Matters
This 8-K filing provides investors with an update on Sionna Therapeutics' financial performance and condition, which is crucial for assessing the company's stability and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not appear to contain any significant new risks or negative developments.
Key Players & Entities
- Sionna Therapeutics, Inc. (company) — Registrant
- March 20, 2025 (date) — Date of Report
- 21 Hickory Drive, Suite 500, Waltham, MA 02451 (address) — Principal executive offices
FAQ
What specific financial information is being reported in this 8-K filing?
The filing indicates it pertains to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
When was this 8-K report filed?
The report was filed on March 20, 2025.
What is the principal business address of Sionna Therapeutics, Inc.?
The principal executive offices are located at 21 Hickory Drive, Suite 500, Waltham, MA 02451.
What is the Commission File Number for Sionna Therapeutics, Inc.?
The Commission File Number is 001-42504.
What is the SIC code for Sionna Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 20, 2025 regarding Sionna Therapeutics, Inc. (SION).